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Abstract
Pharmacogenomics is one of the ﬁ  rst 
clinical applications of the postgenomic 
era. It promises personalized medicine 
rather than the established “one size 
ﬁ  ts all” approach to drugs and dosages. 
The expected reduction in trial and 
error should ultimately lead to more 
efﬁ  cient and safer drug therapy. In 
recent years, commercially available 
pharmacogenomic tests have been 
approved by the Food and Drug 
Administration (FDA), but their 
application in patient care remains 
very limited. More generally, the 
implementation of pharmacogenomics 
in routine clinical practice presents 
signiﬁ  cant challenges. This article 
presents speciﬁ  c clinical examples 
of such challenges and discusses 
how obstacles to implementation of 
pharmacogenomic testing can be 
addressed.
Introduction
In 2003 the International Human 
Genome Sequencing Consortium 
declared that the Human Genome 
Project had been completed, raising 
expectations of clinical application in 
the near future. Pharmacogenomics 
(PGx) (here used synonymously with 
pharmacogenetics [Box 1]), promising 
the end of “one size ﬁ  ts all” drugs and 
of trial and error in pharmacotherapy, 
is often predicted to be one of the ﬁ  rst 
such applications [1]. 
The concept of interindividual 
differences in drug response was 
proposed as early as 1909 by Garrod 
in his book The Inborn Errors of 
Metabolism [2]. Today, the concept 
of PGx, namely that variation in 
drug response is related to genetic 
variation, is widely recognized. Two 
commercially available PGx tests that 
support the personalization of drug 
treatment have already received FDA 
approval. The tests detect variations in 
the genes coding for enzymes involved 
in drug metabolism: cytochrome 
P450 CYP2C19 and CYP2D6 (Roche 
AmpliChip, http:⁄⁄www.roche.com/), 
and UDP-glucuronosyltransferase 
(Invader UGT1AI Molecular Assay; 
Third Wave Technologies, http:⁄⁄www.
twt.com/). Examples of these and 
other PGx tests actually being used 
in patient care are sparse, however. 
Recent surveys in Germany and 
Australia reported that only a small 
number of laboratories offer PGx 
testing for clinical use [3,4]. Current 
and potential future uses of PGx tests 
are summarized in Table 1. 
This article focuses on challenges 
in the translation of PGx to clinical 
practice. Six challenges associated with 
consecutive phases in the translation 
process are discussed (Figure 1). 
Each of the identiﬁ  ed challenges is 
exempliﬁ  ed by situations from clinical 
practice, and possible approaches to 
overcome them are discussed.
Players in the Field
In the challenges presented in Figure 
1, several “players” can be identiﬁ  ed 
[5], including the biotechnology and 
analytical industry, the pharmaceutical 
industry, research institutions, 
funding agencies, regulatory agencies, 
clinicians, and patients. These players 
each have substantial roles, both 
individually and in collaboration, in 
developing and implementing clinical 
applications of PGx.
As an early step in this process, 
the biotechnology and analytical 
industry must develop fast, reliable, 
and affordable assays for routine PGx 
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FIVE KEY PAPERS IN THE FIELD
Van den Akker-van Marle et al., 
2006 [26] Provides evidence that TPMT 
genotyping prior to thiopurine treatment 
initation is cost effective in children with 
acute lymphoblastic leukemia. 
Gardiner et al., 2005 [4] The authors 
demonstrate that PGx tests for drug 
metabolizing enzymes are rarely 
performed in clinical practice.
Sconce et al., 2005 [41]. In this paper 
VKORC1 genotype is combined with 
CYP2C9 genotype to explain outcome of 
warfarin treatment.
Phillips et al., 2004 [22] Systematic 
review of literature data concerning the 
cost effectiveness of PGx interventions.
Kirchheiner et al., 2001 [30] First paper 
on deriving dose recommendations from 
pharmacokinetic study data.PLoS Medicine  |  www.plosmedicine.org 1318 August 2007  |  Volume 4  |  Issue 8  |  e209
measurement. The reaction of the 
pharmaceutical industry to the concept 
of PGx has been reserved, possibly 
because of the potential for market 
segmentation and an end to the era 
of blockbuster drugs (Box 2) [5]. 
Nonetheless, a 2001 report stated that 
by applying genomics technologies, 
the investments to develop a drug 
could be reduced by as much as $300 
million and two years [6]. Further, 
the inﬂ  uence of the pharmaceutical 
industry on the translation of PGx 
to the clinic, although considerable, 
should not be overestimated. 
Manufacturers can be expected to 
pursue development of PGx tests only 
for new compounds and not for drugs 
already marketed. The latter would 
most likely be of interest to research 
institutions, for example academic 
medical centers. 
Indeed, most of our PGx knowledge 
comes from clinical studies initiated by 
research institutions. The importance 
of adequately designed original studies 
on associations between genetic 
variation and clinical drug response 
needs to be recognized by funding 
agencies, including health insurers and 
governmental agencies [7]. In recent 
years, many projects have been funded, 
and even prospective studies on dose 
recommendations are now being 
performed. In addition, these agencies 
will have to be convinced to reimburse 
routine PGx testing, which will 
require extensive information on cost-
effectiveness and cost-consequences of 
PGx testing. 
Regulatory agencies, such as the 
European Agency for the Evaluation 
of Medicinal Products and the FDA 
could play a role by recommending 
or requiring PGx testing for certain 
drugs, which would obviously provide 
a strong stimulus. In 2004 and 2005 
the FDA approved label changes of 
6-mercaptopurine and irinotecan 
to include PGx information; 
recommendations for other drugs, such 
as warfarin, may follow [8,9]. In the 
case of irinotecan, however, results not 
fully supporting the dose adjustment 
included in the label change have been 
reported [10]. To date, mandatory 
testing is mentioned only in the 
package insert of trastuzumab [11]. 
The FDA has issued a guidance for 
industry on the subject of PGx and is 
encouraging voluntary data submission 
[12]. More recently the FDA and the 
European Agency for the Evaluation of 
Medicinal Products have issued a joint 
procedure for the voluntary submission 
of PGx data [13]. 
Following the increase of evidence 
of clinical relevance and number of 
available tests, physicians and clinical 
pharmacists need to become informed 
about the usefulness and also the 
limitations of PGx tests in patient care. 
Patients and patient advocacy groups 
also can have signiﬁ  cant inﬂ  uence on 
PGx implementation.
Challenges for Implementation of 
PGx
Providing scientiﬁ  c evidence for 
improvement in patient care by PGx 
testing. On 16 August 2006, a search 
we did of the medical literature with 
the MeSH term “pharmacogenetics” 
on PubMed resulted in 3,347 hits, 
of which 1,487—almost 45%—were 
review articles. The relative paucity of 
original research articles is not the only 
problem. Many original articles involve 
a small, speciﬁ  c study population, 
administration of single doses, use of 
doi:10.1371/journal.pmed.0040209.g001
Figure 1. Consecutive Phases and Associated Challenges on the Road to Clinical 
Implementation of Pharmacogenomics
Table 1. Use of PGx in Clinical Practice
Current Future
Primarily diagnostic; retrospective Prevention of toxicity and treatment optimization; 
prospective
Speciﬁ  c test in individual  Population-wide screening 
Focus on adverse drug events  Focus on therapy selection 
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healthy volunteers instead of patients, 
or use of a different translation from 
genotype to phenotype. Moreover, 
most positive association studies 
lack validation of ﬁ  ndings in an 
independent patient population. 
A classic application of PGx, often 
used as an example of its potential 
clinical consequences, involves the 
variable effect of the antidepressant 
nortriptyline (NT) due to differences 
in the gene encoding cytochrome 
P450 family member CYP2D6. The 
plasma levels of NT may vary almost 
10-fold depending on the number of 
functional CYP2D6 alleles. However, 
the scientiﬁ  c literature reveals a lack 
of solid evidence that, in the case 
of NT, the CYP2D6 polymorphisms 
actually lead to signiﬁ  cant clinical 
consequences, such as increased 
toxicity or decreased drug efﬁ  cacy. 
The Pharmacogenetics Working 
Party of the Royal Dutch Society for the 
Advancement of Pharmacy is working 
to implement PGx into their automated 
medication control database, which is 
to be used in computerized physician 
and pharmacist order entry systems 
(http:⁄⁄farmacogenetica.knmp.nl/). 
Table 2 summarizes their recently 
conducted systematic literature 
search for evidence to deﬁ  ne NT dose 
recommendations for different CYP2D6 
genotype-predicted phenotypes (search 
terms available upon request).
Only nine scientiﬁ  c articles 
concerning the interaction between 
CYP2D6 and NT, encompassing a total 
study population of 193 participants, 
could be retrieved. Among these 
participants there were only 15 
poor metabolizers and 12 ultrarapid 
metabolizers (UM). Furthermore, the 
studies frequently were single-dose 
experiments with healthy volunteers 
or were limited to speciﬁ  c populations, 
such as Korean inhabitants or geriatric 
patients. Most study end points were 
pharmacokinetic, conﬁ  rming that 
CYP2D6 genotype has an impact on NT 
pharmacokinetics. However, no drug 
efﬁ  cacy or toxicity data were reported. 
Therefore, even for what is considered 
a classic example of PGx, solid scientiﬁ  c 
evidence for clinical relevance is still 
lacking. In a recent article Kirchheiner 
et al. [14] provide an overview of how 
better-designed studies are needed 
for the clinical breakthrough of PGx 
and how this breakthrough could be 
realized by a more systematic inclusion 
of PGx in drug development.
Selecting clinically relevant PGx 
tests. Research in the ﬁ  eld of PGx 
should be focused on the development 
of diagnostic tests for clinically 
important problems. Not every 
association study leads to a potentially 
useful PGx test, and ﬁ  nancial and 
technical resources may be wasted if the 
relevance of more readily measurable 
values is not excluded ﬁ  rst [15]. For 
example, the 5-hydroxytryptamine 3 
receptor antagonists used to prevent 
nausea and vomiting are known to 
be metabolized by CYP2D6. Kim 
et al. showed genotype-dependent 
pharmacokinetics in healthy volunteers 
for tropisetron [16], suggesting a 
hypothesis that cancer patients who 
are UM are undertreated by a standard 
dose of tropisetron. This hypothesis 
was studied by Kaiser and colleagues 
in 270 cancer patients. Patients with 
a high number of functional CYP2D6 
alleles experienced more nausea and 
episodes of vomiting [17]. A similar 
result was found in patients receiving 
4 mg of ondansetron to prevent 
postoperative nausea and vomiting 
[18]. These ﬁ  ndings clearly show 
In many publications the terms 
pharmacogenetics (PGt) and 
pharmacogenomics (PGx) are used 
interchangeably while others distinguish 
between the two concepts [54–56]. 
We prefer to use the single term PGx 
with the following deﬁ  nition: “the 
individualization of drug therapy through 
medication selection or dose adjustment 
based upon direct (e.g., genotyping) or 
indirect (e.g., phenotyping) assessment 
of a person’s genetic constitution for 
drug response.” This deﬁ  nition includes 
tests operating at protein, metabolite, or 
other biomarker levels whenever these 
factors are affected by genetic variation 
(i.e., single nucleotide polymorphisms, 
insertions, deletions, microsatellites, 
variance in copy number, etc). Both 
germline (i.e., heritable mutations) as well 
as somatic mutations (i.e., nonheritable 
mutations in, for example, tumor 
specimens) are considered. Therefore, 
immunohistochemical tests such as that 
for HER2/neu are considered a PGx test in 
the context of this article.
Box 1. A Matter of Deﬁ  nitions
doi:10.1371/journal.pmed.0040209.g002
Figure 2. The Use of the Calvert Formula in Clinical Trials from 1989 to 1998
A PubMed search for the dosing of carboplatin in clinical trials was performed for the period 
1989–1998. For each year the ﬁ  rst ten results of PubMed were screened for the use of the 
Calvert formula. Bars represent the percentage of results in which the Calvert formula was 
used to dose carboplatin (A), the Calvert formula was not used (B), or no dosing information 
could be retrieved electronically (C).PLoS Medicine  |  www.plosmedicine.org 1320 August 2007  |  Volume 4  |  Issue 8  |  e209
the inﬂ  uence of UM phenotype on 
both pharmacokinetics and clinical 
effectiveness of 5-hydroxytryptamine 3 
receptor antagonists. However, due to 
the low prevalence of UM genotype in 
people of northern European descent, 
the “number needed to genotype” 
(i.e., the number of patients needed 
to genotype in order to prevent one 
patient from unnecessary nausea 
and vomiting) appeared to be 50. 
This number is probably too high to 
implement this PGx test into routine 
clinical practice and, more importantly, 
easier methods such as dose titration 
or the use of an alternative antiemetic 
regimen are already available to 
prevent nausea [19]. PGx studies 
should be encouraged in ﬁ  elds 
where the likelihood of a clinically 
relevant effect is high and its potential 
usefulness is evident in clinical practice 
(Table 3).
Providing data on diagnostic test 
criteria of PGx testing. To be clinically 
useful, a PGx test must predict the 
outcome of drug treatment. Complex 
pathways are involved in the action 
and metabolism of most drugs, and 
nongenetic inﬂ  uences also contribute 
to drug response [15]. Therefore, PGx 
testing for single polymorphisms may 
account for only part of the variability 
in drug response. The diagnostic test 
criteria sensitivity, speciﬁ  city, and 
predictive value are applicable to tests 
for which response is determined as a 
dichotomous variable. However, drug 
response cannot always be considered 
an all-or-none phenomenon. In these 
situations the relative contribution 
of the genotype to the variability in 
Table 2. Evidence for Nortriptyline Dose Adjustments Based on PGx
Population Dose (mg/d) Single (S) or 
Multiple Dose (M)
End Point Outcome Reference
Single patient 150 M Clinical Develops plasma concentration of 0.471 mg/ml, dry mouth, 
constipation, and dizziness
[61]
36 geriatric patients  Titrated to Css of 
0.050–0.150 mg/ml
M Kinetic Dose corrected Css (IM + PM) was 2.2 times Css (EM) [62]
Average IM + PM dose was 30% lower than EM
A correlation between the number of alleles encoding decreased 
metabolism, Css, dose, and dose corrected Css,
Effect co medication not clear
Ten healthy native 
Korean volunteers
25 S Kinetic No signiﬁ  cant difference in Cmax, tmax, t1/2, AUC for NT, or  10-OH-NT 
between homo- and heterozygous
[63]
41 Japanese patients 15–120 M Kinetic Dose-corrected Css WT/mut was 1.4 times Css WT/WT [64]
Dose-corrected Css mut/mut was 2.1 times Css WT/WT
Dose-corrected Css mut/mut E-10-OH-NT was 0.66 times Css WT/WT
15 healthy Chinese 
volunteers
25 S Kinetic No signiﬁ  cant difference in t1/2, AUC for NT between homo- and 
heterozygous EM
[65]
IM: t1/2 and AUC of NT were raised 1.8 and 2.2 times, respectively, 
compared to EM
IM: t1/2 of 10-OH-NT was 1.9 times t1/2 EM
21 white patients 150 M Kinetic IM: Dose corrected Css of 10-OH-NT was 0.7 times Css EM [66]
PM: Dose corrected Css of NT was 2.5 times Css EM
PM: Dose corrected Css of 10-OH-NT was 0.9 times Css EM
Eight patients with 
adverse drug reaction
10–100 M Clinical 44% were carriers of ≥1 mutant allele compared to 21% in 56 
control psychiatric patients
[67]
Co-medication unknown
21 healthy white 
volunteers
25–50 S Kinetic IM: t1/2 and AUC NT were raised 2.3 and 2.8 times respectively 
compared to EM
[68]
IM: t1/2 of 10-OH-NT was 1.9 times t1/2 EM
PM: t1/2 and AUC NT were raised 2.6 and 3.3 times, respectively, 
compared to EM
PM: t1/2 of 10-OH-NT was 2.4 times t1/2 EM
UM (three alleles): t1/2 and AUC NT were raised 0.9 and 0.76 times, 
respectively, compared to EM
UM (three alleles): t1/2 of 10-OH-NT was 0.82 times t1/2 EM
UM (13 alleles): t1/2 and AUC NT were raised 0.9 and 0.20 times, 
respectively, compared to EM
UM (three alleles): t1/2 of 10-OH-NT was 0.4 times t1/2 EM
20 healthy volunteers 
and 20 patients
25–150 Both Kinetic IM: Cl, t1/2, F, NT were raised 0.8, 1.2, 1.2 times, respectively, 
compared to EM
[69]
PM: Cl, t1/2, F, NT were raised 0.6, 1.8, 1.4 times, respectively, 
compared to EM
UM: Cl, t1/2, F, NT were raised 1.3, 0.9, 0.8 times, respectively, 
compared to EM
Co-medication unknown
10-OH-NT, 10-hydroxynortriptyline; AUC, area under the plasma drug concentration-time curve; Cl, clearance; Css, steady state plasma concentration; EM, extensive metabolizer; F, 
bioavailability; IM, intermediate metabolizer; mut, mutant allele; NT, nortriptyline; PM, poor metabolizer; t1/2, elimination half-life; UM, ultrarapid metabolizer; WT, wild type 
doi:10.1371/journal.pmed.0040209.t002PLoS Medicine  |  www.plosmedicine.org 1321 August 2007  |  Volume 4  |  Issue 8  |  e209
response (the percentage explained 
variance, R2) provides additional 
information. Diagnostic test criteria 
of PGx tests are not commonly 
reported, but are important for clinical 
implementation. Table 4 summarizes 
the characteristics of selected PGx tests. 
It can be observed that the 
diagnostic test criteria for PGx tests 
are comparable to those of clinically 
available non-PGx tests (also shown in 
Table 4). Thus, while some consider 
current PGx tests as having inadequate 
value for clinical application, tests with 
comparable diagnostic test criteria 
are currently being used in patient 
care. The need for well-deﬁ  ned 
PGx test criteria has been previously 
discussed [20,21]. We maintain that 
demonstration of potential clinical 
usefulness requires the reporting 
of diagnostic test criteria in PGx 
association studies.
Providing information on cost-
effectiveness and cost-consequences 
of PGx testing. Although funding 
agencies including health insurers have 
funded many PGx research projects 
in recent years, their willingness 
to reimburse routine PGx testing 
will require information on cost-
effectiveness and cost-consequences. In 
2004, Phillips performed a systematic 
literature review on cost-effectiveness 
of PGx testing [22]. Only 11 published 
true cost-effectiveness analyses (CEAs) 
could be retrieved. Seven studies 
found a PGx-based strategy to be 
cost-effective, two showed equivocal 
results, and two concluded that a PGx-
based strategy was not cost-effective. 
Despite the publication of additional 
CEAs of PGx, there is a need for more 
information [23–26]. The performance 
of such CEAs is problematic for two 
reasons. First, there are limited data on 
the rate at which PGx testing actually 
prevents adverse drug reactions. 
Second, PGx test prices are dropping 
continuously. Even without data 
from a comprehensive CEA, some 
simple calculations can be made and 
preliminary conclusions can be drawn 
on potential cost-effectiveness of PGx 
testing (Box 3).
The example in Box 3 indicates 
that screening for dihydropyrimidine 
dehydrogenase (DPD) deﬁ  ciency in all 
5-ﬂ  uorouracil (5FU)-treated patients 
is not cost-effective, mainly due to the 
low incidence of DPD deﬁ  ciency and 
the high cost of the phenotypic assay. It 
might become cost-effective if the cost 
of the assay decreases. Circumstances 
that favor the cost-effectiveness of PGx 
testing include high prevalence of the 
relevant allelic variant in the target 
population, good correlation between 
genotype and phenotype, satisfactory 
diagnostic test criteria, phenotype 
associated with signiﬁ  cant morbidity 
or mortality if left untreated, and 
signiﬁ  cant reduction in adverse drug 
reactions reduction by PGx testing 
[27].
Although the necessity of CEAs 
for every new clinical technique is 
debatable, and several innovations have 
found their way to application without 
proof of their cost-effectiveness [28,29], 
more research on the cost-effectiveness 
and cost-consequences of PGx testing 
will nonetheless stimulate its further 
implementation into clinical practice.
Developing guidelines directing the 
clinical use of PGx test results. PGx 
studies published to date usually report 
that carriers of a speciﬁ  ed genotype 
in a particular patient population 
have an increased likelihood of a 
desired (or undesired) outcome of 
drug treatment. Such studies have not, 
however, resulted in the distillation of 
practical prescribing recommendations 
based on genotype. In particular, very 
little data are available on effective 
and safe dose adjustment for the 
different metabolizer phenotypes, 
although a 2001 consensus paper 
on deriving CYP2D6 phenotype-
related dose recommendations for 
antidepressants from pharmacokinetic 
study data represents an early step 
[30]. Coumarins used in the treatment 
and prevention of venous and 
thromboembolic disorders constitute 
one case in which the application of 
dose recommendations is relatively far 
advanced. Coumarins (e.g., warfarin, 
phenprocoumon, acenocoumarol) 
are primarily metabolized by CYP2C9, 
and treatment outcome is known to be 
associated with CYP2C9 genotype [31–
39]. More recently, the gene coding 
for the vitamin K epoxide reductase 
subunit 1 (VKORC1) was found to 
contribute to the variability in response 
observed in warfarin users [40]. 
Table 3. High Likelihood of Clinical Relevance of PGx Test
Drug Characteristics
Narrow therapeutic index (i.e., high chance of toxicity)
Difﬁ  culty predicting response or adverse effect
Large interindividual variability in response
Consistent PK-PD relationship
Long-term treatment
doi:10.1371/journal.pmed.0040209.t003
The potentially smaller market for 
a drug could be compensated by (1) 
an increased rate of adoption of the 
drug; (2) the identiﬁ  cation of patients 
who otherwise would not have been 
candidates for the drug; (3) increased 
compliance with improved efﬁ  cacy; and 
(4) the possibility of premium pricing 
[57]. This process can be illustrated with 
preliminary calculations of the use of the 
tumor necrosis factor alpha-blocking 
drug adalimumab used in the treatment 
of rheumatoid arthritis. 
The prevalence of rheumatoid 
arthritis in adults in The Netherlands is 
1%, resulting in approximately 160,000 
potential users of adalimumab. The 
estimated cost for the treatment of all 
these patients with adalimumab during 
one year is about €1,900,000,000. To 
limit the costs, the use of adalimumab 
has been restricted to treatment of 
patients with moderate to severe 
rheumatoid arthritis failing to respond 
on disease-modifying antirheumatic 
drugs or methotrexate. As a result, only 
3,440 patients, or 2.15% of the potential 
160,000, used the drug in 2005. When a 
certain PGx test enables predicting the 
response to adalimumab, there would be 
no legitimate reason to withhold the drug 
from the predicted responders; and if the 
prevalence of the responsive genotype 
were to exceed 2.15% in the rheumatoid 
arthritis patient population the revenues 
of the manufacturer would increase.
Box 2. PGx Need Not Be Financially Unattractive from a Drug 
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The effect of CYP2C9 and VKORC1 
genotype combined with patient height 
explained up to 55% of variance in 
warfarin dose [41]. Two prospective 
(pilot) studies concluded that the use 
of an algorithm including CYP2C9 
genotype for warfarin dosing is feasible 
[42,43], and prospective research 
is ongoing in the UK. Therefore, 
prospectively validated coumarin 
dosing algorithms that include PGx 
information might become available 
in the near future. In more recent 
developments, Wessels et al. have 
developed a clinical scoring system 
based on seven factors, including four 
genetic polymorphisms, to predict 
efﬁ  cacy of methotrexate monotherapy 
in rheumatoid arthritis patients. They 
provide a tool that translates the 
outcome of the model into individual 
treatment recommendations [44]. 
De Leon et al. have published clinical 
guidelines for using CYP2D6 and 
CYP2C19 genotypes in the prescription 
of antidepressants or antipsychotics 
[45]. Further translational research 
aimed speciﬁ  cally at the practical 
application of PGx in clinical situations 
is warranted. 
Improving acceptance of PGx 
testing. A newly introduced drug or 
technology is normally ﬁ  rst applied 
by a small group of clinicians. In time 
it may become standard treatment 
incorporated into guidelines and 
consequently into wider clinical 
use. The time from introduction to 
acceptance of new methods may vary 
widely, as illustrated by a comparison 
of the implementation of Calvert’s 
formula with that of HER2/neu testing. 
Carboplatin is currently dosed using 
the formula of Calvert, published in 
1989, for area-under-the-curve targeted 
dosing [46]. Attention was called to 
Calvert’s formula several times but it 
was not until 1996 that it was reported 
by the American Hospital Formulary 
Service, a widely used source of drug 
information [47,48]. Assuming that 
uptake into guidelines to some extent 
represents clinical acceptance, this 
time course shows that it took no less 
than seven years for Calvert’s formula 
to be accepted. This relatively slow 
acceptance is further exempliﬁ  ed 
by the limited use of the formula in 
clinical trials with carboplatin during 
the early 1990s (Figure 2).
The cytotoxic drug 5FU is widely 
used, for example in colorectal cancer. 
Severe neutropenia is associated with 
deﬁ  ciency of the enzyme DPD, which 
metabolizes 5FU [58]. The deﬁ  ciency of 
DPD is thought to be caused by germline 
mutations in the gene encoding DPD.
A possible strategy would be to 
test all 5FU-treated patients, and we 
estimate the cost consequences for 
the Dutch situation as follows. About 
7,000 patients per year are treated with 
5FU. A phenotypic test measuring DPD 
activity in peripheral mononuclear 
cells is available, and normal values 
for enzyme activity in both wild-type 
and heterozygotes are known, but 
are relatively difﬁ  cult to distinguish. 
The incidence of DPD deﬁ  ciency 
is about 3% and, therefore, 210 
patients of the 7,000 5FU-treated patients 
may be detected by this test [59]. 
In a meta-analysis on 5FU-related 
toxicity it was reported that the incidence 
of 5FU-related death is about 0.5%, 
and in 50% of the cases toxicity was 
explained by deﬁ  ciency of the enzyme 
DPD [60]. The cost of the DPD assay is 
€850, which would result in an estimated 
cost of nearly €6 million to test all 7,000 
patients for DPD status. This testing 
would save 17 patients per year, at a cost 
of €350,000 per saved life, which may 
be unrealistically high. Moreover, even 
then, 17 other patients will die from 5FU-
related toxicity anyway, because their 
toxicity is not related to DPD deﬁ  ciency. 
Although this example is evaluated in a 
Dutch setting the data and conclusion 
can be applied to other settings.
Table 4. Comparison of Diagnostic Test Criteria of a Selection of PGx Tests and Non-PGx Tests Used in Clinical Practice
Test Category Biomarker Form Associated Effect N Sensitivity Speciﬁ  city PPV NPV R2 Ref
PGx tests CYP2C9*3 polymorphism SNPs Risk of bleeding complication 185 0.17 0.94 0.40 0.82 NA [39]
Carrier of a CYP2C9 and 
VKORC1 polymorphism
SNPs Acenocoumarol-induced 
overanticoagulation (INR>6)
226 0.48a 0.81a 0.20a 0.94a 39.1 [70]
5-lipoxygenase (Alox5) 
genotype
Tandem 
repeat
Response to leukotriene 
antagonist ABT761
221 1a 0.17a 0.52a 1a NA [71]
UGT1A1-3156AA 
genotype
SNP Grade 4 neutropenia and 
irinotecan in whites
66 0.50 0.96 0.60 0.95 24 [72]
β1 receptor
Arg389Arg genotype
SNPs Reduction in daytime 
diastolic blood pressure
40 0.78a,b 0.82a,b 0.78a,b 0.82a,b 15.8 [73]
HLA-B*5701 genotype SNPs Hypersensitivity to abacavir 
in whites
1821 0.46–0.94 0.90–0.98 0.19–0.81 0.97–0.99 NA [74]
Non-PGx tests used 
in clinical practice
Rheumatoid factor 
positivity
Radiologic progression 110 0.84 0.54 0.77a 0.75a 11 [75]
Prostate speciﬁ  c antigen 
(> 4.0 ng/ml)
Prostate cancer 284 0.68–0.75 0.6–0.71 0.51–0.54 0.73–0.87 NA [76]
Troponin T (> 0.1 ng/ml) Acute myocardial infarction 773 0.94a 0.89a 0.36a 1a NA [77]
Borrelia burgdorferi 
antigen
Lyme disease 43 0.77 0.83-1 0.19-1c 0.99c NA [78]
aCalculated from reported results.
bResponse deﬁ  ned as ≥10% reduction in daytime diastolic blood pressure from baseline.
cCalculated with a positive serum prevalence of 5%.
N, number of study participants; NA, not applicable; NAT, N-acetyltransferase 2; NPV, negative predictive value; PPV, positive predictive value; R2, percentage explained variance; SNP, 
single nucleotide polymorphism; UGT1A1, UDP-glucuronosyltransferase.
doi:10.1371/journal.pmed.0040209.t004
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A contrasting example is the 
implementation of testing of breast 
cancers for HER2/neu overexpression 
with immunohistochemistry or 
ﬂ  uorescence in situ hybridization to 
select patients with metastasized breast 
cancer eligible for treatment with 
trastuzumab. In the late 1980s and early 
1990s, several studies demonstrated 
that breast cancers with HER2/neu 
overexpression showed poor prognosis 
[49–  53]. In 1998 trastuzumab, a 
monoclonal drug directed against the 
HER2 protein, was launched on the 
US market. One year later, testing 
for HER2/neu overexpression was 
included in the American Hospital 
Formulary Service trastuzumab 
monograph. Testing for HER2/neu 
overexpression has become standard 
practice for guiding drug therapy for 
metastatic breast cancer. In contrast to 
the lengthy time line for acceptance of 
Calvert’s formula, the short time line 
of acceptance of testing for HER2/
neu overexpression indicates that fast 
uptake is possible. The two examples 
differ in many respects (e.g., one results 
in a dose adjustment while the other 
results in the decision whether or not 
to prescribe the drug). Nonetheless, 
two differences might be observed 
to present potential opportunities 
for improved clinical uptake of PGx. 
First, the use of testing for HER2/neu 
overexpression was required by the 
regulatory agencies upon market 
introduction of trastuzumab. With 
regard to PGx testing, this requirement 
suggests that obligatory testing prior to 
drug prescribing might give a strong 
stimulus to the clinical uptake of PGx. 
Second, HER2/neu testing was actively 
advocated by the pharmaceutical 
company manufacturing the drug and 
by patient advocacy organizations. 
Similarly active support for the use 
of clinically established PGx tests by 
pharmaceutical companies or patient 
advocacy organizations might be 
expected to improve clinical uptake of 
PGx testing.
Conclusions
Because variation in drug responses 
is, at least to some extent, related to 
genetic variation, PGx testing has the 
potential to result in safer and more 
effective use of drugs by permitting 
individualized therapy. In recent years 
FDA-approved PGx tests have become 
available, but the use of PGx testing 
has remained limited, largely by a lack 
of scientiﬁ  c evidence for improved 
patient care by PGx testing. Providing 
this scientiﬁ  c evidence presents a 
signiﬁ  cant challenge. The development 
of novel tests should be aimed at 
solving important clinical problems. To 
demonstrate potential for clinical use, 
PGx studies should report diagnostic test 
criteria. For PGx tests shown to improve 
patient care, guidelines directing the 
clinical use of PGx test results should 
be developed. Information on cost-
effectiveness and cost-consequences 
of PGx testing should be provided to 
facilitate reimbursement by insurance 
companies. Finally, uptake in clinical 
practice will be given a stimulus if 
regulatory agencies recommend testing 
prior to prescribing the drug, and if 
pharmaceutical companies or patient 
groups advocate for use of the test. If 
the outlined challenges can be met, the 
incorporation of PGx in routine clinical 
practice may prove an achievable goal in 
the near future.  
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